The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.

Scope

In-depth analysis of the market for systemic antifungals covering Japan, US, France, Italy, Germany, Spain and the UK Product by product analysis of the key marketed and pipeline brands that will determine the market's evolution An assessment of key unmet needs and the opportunities they offer for new product development Key considerations for trial design as pre-emptive and targeted strategies replace prophylactic and empiric strategies

Highlights

Over the 2002 to 2006 period, the market for systemic antifungals has risen by a moderate 3.3% from $2.7billion to $3.1 billion; however, its value has dropped by 7.4% between 2005 and 2006. The US and M5EU launch of the next wave of echinocandins (Eraxis and Mycamine) and the next generation azoles (Vfend and Noxafil) will shorten the current period of devaluation of the market caused by widespread uptake of generic fluconazole and itraconazole. New diagnostic technology promises to offer clinicians far better decision making tools, emphasizing the need for a rethink of antifungal clinical trial design. Innovative approaches will be needed to ensure that already costly trials do not become prohibitively expensive, while remaining clinically relevant.

Reasons to Purchase

Understand clinical and commercial impact of key marketed and pipeline products on the future shape of the systemic fungal infections market Understand the key clinical analysis that will be essential to cater to clinicians' information needs and gain widespread use Review the impacts of new diagnostic techniques on antifungal treatment strategies